SOUTH SAN FRANCISCO, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Bittoo Kanwar, M.D., chief medical officer, and Liz Bhatt, chief business and strategy officer, will participate in

Top-line data readout for oral AMT-101 Phase 2 MARKET combination trial with anti-TNF α in ulcerative colitis (UC) expected in H1 2022 Top-line data readouts from three additional oral AMT-101 Phase 2 trials, consistent with previous guidance FILLMORE monotherapy trial in pouchitis in H1 2022

Management to highlight novel oral biologics technology platform, clinical programs and research activities Feature distinguished IBD and rheumatology key opinion leaders Provide update on the four on-going Phase 2 clinical trials for oral AMT-101 SOUTH SAN FRANCISCO, Calif., Oct.

SOUTH SAN FRANCISCO, Calif., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that the company will participate in the following investor events in September and October.

SOUTH SAN FRANCISCO, Calif., Aug. 24, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced the appointment of Holly Schachner, M.D. a seasoned and accomplished industry veteran to its Board of Directors.

Top-line data readouts expected from four Phase 2 trials of oral AMT-101, consistent with previous guidance Combination trial of AMT-101 with anti-TNF α in moderate-to-severe ulcerative colitis (UC) patients in the fourth quarter of 2021; Monotherapy trial in pouchitis, combination trial with

SOUTH SAN FRANCISCO, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood, Ph.D., chief executive officer and co-founder, will participate in a fireside chat during Canaccord

Once daily, oral AMT-101 was safe and well tolerated, and demonstrated trends of improvement in objective measures of inflammation: fecal calprotectin, CRP, and histology Key findings support oral AMT-101 actively exerts immunomodulatory effect resulting in local and systemic benefit Microbiome

SOUTH SAN FRANCISCO, Calif., June 09, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood, Ph.D., chief executive officer and co-founder, will participate in a fireside chat during the JMP

SOUTH SAN FRANCISCO, Calif., May 26, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood, Ph.D., chief executive officer and co-founder, will participate in a fireside chat during the